BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30288353)

  • 1. MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment.
    Hu J; Sun J
    Oncoimmunology; 2018; 7(10):e1487914. PubMed ID: 30288353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring
    Wang Q; Yang Y; Yang M; Li X; Chen K
    Aging (Albany NY); 2020 Jun; 12(11):10827-10843. PubMed ID: 32491995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.
    Sun L; Wang RC; Zhang Q; Guo LL
    Pathol Res Pract; 2020 Aug; 216(8):153032. PubMed ID: 32703496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
    Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
    Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
    Li X; Pasche B; Zhang W; Chen K
    JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of
    Wang Z; Hou H; Zhang H; Duan X; Li L; Meng L
    Am J Transl Res; 2022; 14(2):849-862. PubMed ID: 35273689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why
    Huang YJ; Cao ZF; Wang J; Yang J; Wei YJ; Tang YC; Cheng YX; Zhou J; Zhang ZX
    World J Clin Cases; 2021 Jun; 9(17):4143-4158. PubMed ID: 34141777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.
    Wu Y; Liu Q; Xie Y; Zhu J; Zhang S; Ge Y; Guo J; Luo N; Huang W; Xu R; Liu S; Cheng Z
    J Ovarian Res; 2023 Aug; 16(1):181. PubMed ID: 37644468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
    Li Y; Bian Y; Wang K; Wan XP
    BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.
    Fan K; Yang C; Fan Z; Huang Q; Zhang Y; Cheng H; Jin K; Lu Y; Wang Z; Luo G; Yu X; Liu C
    Cancer Lett; 2018 Apr; 418():167-175. PubMed ID: 29337110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of MUC16 predicts favourable prognosis in MUC16-mutant cervical cancer related to immune response.
    Wang H; Yan C; Ye H
    Exp Ther Med; 2020 Aug; 20(2):1725-1733. PubMed ID: 32765681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
    Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
    Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
    Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
    J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC16 mutation predicts a favorable clinical outcome and correlates decreased Warburg effect in gastric cancer.
    Zhao H; Zhang L
    Biochem Biophys Res Commun; 2018 Dec; 506(4):780-786. PubMed ID: 30389134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association of
    Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
    Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment.
    Wang X; Duanmu J; Fu X; Li T; Jiang Q
    J Transl Med; 2020 Aug; 18(1):324. PubMed ID: 32859214
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Kanwal M; Ding XJ; Song X; Zhou GB; Cao Y
    Oncotarget; 2018 Feb; 9(15):12226-12239. PubMed ID: 29552305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.